Answers are grounded in this paper and cite their sources.
Drug discovery is a continuously evolving area, essential for mankind albeit a very expensive process with a high attrition rate. The main challenge faced by pharmaceutical researchers today is to identify the major hurdles and validate the “developability” of a compound in the initial stages of drug development in order to select superior drug candidates with the best chances of success. This motivated us to introduce a “universal” approach for analyzing the pharmacodynamics, pharmacokinetics and toxicity profile of compounds based on the philosophy of QSAR. The present work deals with the development, validation and application of a novel QSPR formalism entitled EigenValue ANalySis (EVANS). This methodology encodes 3D structural information in terms of the atom pair distances along with molecular physicochemical properties to generate a set of unique hybrid descriptors, termed as “Eigenvalues.” The present article deals with the intricacies of the methodology and explores its applicability on a series of datasets for building pharmacodynamic QSAR models.
No takes yet. Share an insight, caveat, or question.
Joseph et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: